ICU Medical, Inc. (ICUI) – What Are Analysts Saying About This Stock?

ICU Medical, Inc. (NASDAQ:ICUI) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $192.80.

A number of equities research analysts have recently weighed in on ICUI shares. Weiss Ratings raised ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Needham & Company LLC increased their price objective on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Piper Sandler raised their target price on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, BTIG Research lifted their target price on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, August 7th.

Insider Buying and Selling

In related news, Director Elisha W. Finney sold 378 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the completion of the sale, the director owned 4,871 shares of the company’s stock, valued at $888,860.08. This represents a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ben Sousa sold 2,250 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total transaction of $401,220.00. Following the completion of the sale, the insider directly owned 3,076 shares of the company’s stock, valued at $548,512.32. The trade was a 42.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 21,830 shares of company stock valued at $3,905,003. Company insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc grew its holdings in ICU Medical by 26.2% during the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 65 shares during the period. Nisa Investment Advisors LLC raised its position in ICU Medical by 1.3% in the third quarter. Nisa Investment Advisors LLC now owns 6,088 shares of the medical instruments supplier’s stock worth $977,000 after acquiring an additional 79 shares in the last quarter. California Public Employees Retirement System raised its position in ICU Medical by 0.3% in the first quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock worth $3,934,000 after acquiring an additional 90 shares in the last quarter. Allworth Financial LP lifted its holdings in ICU Medical by 155.1% in the 2nd quarter. Allworth Financial LP now owns 176 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 107 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in ICU Medical by 1.7% in the 2nd quarter. Arizona State Retirement System now owns 6,551 shares of the medical instruments supplier’s stock valued at $960,000 after acquiring an additional 109 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors.

More ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Third-quarter earnings were $2.44 per share, topping the $2.14 analyst consensus and rising from $2.03 a year earlier. Revenue of $556.22 million also beat expectations of $552.03 million and increased 4.4% year over year. Zacks Q3 earnings report
• Positive Sentiment: Management reaffirmed its fiscal 2026 guidance and expects results toward the high end of its range, signaling confidence in its outlook. Company results and guidance
• Negative Sentiment: The guidance was maintained, not increased, and sales growth was 4.4%; those factors may have tempered enthusiasm despite the quarterly beats. Q3 sales report

ICU Medical Trading Down 2.9%

Shares of NASDAQ:ICUI opened at $167.65 on Friday. The company has a market cap of $4.19 billion, a PE ratio of 142.08, a P/E/G ratio of 2.17 and a beta of 0.88. The company’s 50-day moving average price is $162.97 and its 200 day moving average price is $149.18. ICU Medical has a fifty-two week low of $113.37 and a fifty-two week high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.30. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $556.22 million during the quarter, compared to analyst estimates of $552.03 million. During the same period in the previous year, the business posted $2.03 EPS. ICU Medical’s revenue was up 4.4% on a year-over-year basis. Sell-side analysts anticipate that ICU Medical will post 7.22 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.